Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 207,392	$ 183,259
Prepaid expenses and other current assets	1,865	3,267
Total current assets	209,257	186,526
Property, plant and equipment, net	883	650
Operating lease right-of-use assets	2,557	1,914
Other long-term assets	805	341
Total assets	213,502	189,431
Current liabilities:
Accounts payable (including related party amounts of $69 and $1,343, respectively)	5,758	5,150
Accrued clinical trial expenses	341	1,402
Accrued expenses (including related party amounts of $2,501 and $2,330, respectively)	13,783	11,405
Accrued interest	565	477
Operating lease liabilities, current	628	487
Total current liabilities	21,075	18,921
Long-term debt, net of discount	92,432	89,671
Revenue interest financing liability	98,103
Operating lease liabilities	1,392	1,183
Other long-term liabilities	7,500	7,500
Total liabilities	220,502	117,275
Commitments and contingencies (Note 4)
Stockholders’ equity:
Preferred stock, $0.0001 par value; authorized shares - 40,000,000; no shares issued and outstanding at June 30, 2022 and December 31, 2021
Common stock, $0.0001 par value; authorized shares - 400,000,000; issued shares - 39,072,046 and 31,656,035 at June 30, 2022 and December 31, 2021, respectively; outstanding shares - 38,372,403 and 30,511,226 at June 30, 2022 and December 31, 2021, respectively	3	3
Treasury stock - 19 and 1 at June 30, 2022 and December 31, 2021, respectively
Additional paid-in capital	613,952	601,523
Accumulated deficit	(620,955)	(529,370)
Total stockholders' equity (deficit)	(7,000)	72,156
Total liabilities and stockholders’ equity	$ 213,502	$ 189,431